Levin Capital Strategies, L.P. Abb Vie Inc. Transaction History

Levin Capital Strategies, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2022	SELL	$134.21 - $153.93 $67,105 - $76,965	-500 Reduced 15.93%	2,638 $354,000
Q3 2021 Nov 10, 2021	SELL	$106.4 - $120.78 $1.32 Million - $1.5 Million	-12,420 Reduced 79.83%	3,138 $338,000
Q2 2021 Aug 11, 2021	SELL	$105.21 - $117.21 $4.55 Million - $5.07 Million	-43,227 Reduced 73.53%	15,558 $1.75 Million
Q1 2021 May 05, 2021	SELL	$102.3 - $112.62 $27,109 - $29,844	-265 Reduced 0.45%	58,785 $6.36 Million
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $352,465 - $475,865	-4,379 Reduced 6.9%	59,050 $6.33 Million
Q3 2020 Nov 17, 2020	SELL	$85.91 - $100.83 $519,325 - $609,517	-6,045 Reduced 8.7%	63,429 $5.56 Million
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $4.73 Million - $6.33 Million	64,474 Added 1289.48%	69,474 $6.82 Million
Q1 2020 May 13, 2020	BUY	$64.5 - $97.79 $322,500 - $488,950	5,000 New	5,000 $381,000
Q4 2019 Feb 10, 2020	SELL	$72.13 - $90.25 $725,988 - $908,366	-10,065 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$62.98 - $75.72 $633,893 - $762,121	10,065 New	10,065 $762,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Levin Capital Strategies, L.P., based on Form 13F filings with the SEC.

Stay updated on Levin Capital Strategies, L.P. with notifications on news.